PIIIW
PIIIW
P3 Health Partners Inc.Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q3-2025 | $345.25M ▼ | $19.69M ▼ | $-31.59M ▼ | -9.15% ▼ | $-9.67 ▼ | $-27.89M ▼ |
| Q2-2025 | $355.79M ▼ | $389.91M ▲ | $-20.36M ▲ | -5.72% ▼ | $-6.23 ▲ | $-10.46M ▲ |
| Q1-2025 | $373.23M ▲ | $32.31M ▼ | $-20.48M ▲ | -5.49% ▲ | $-6.28 ▲ | $-13.4M ▲ |
| Q4-2024 | $370.69M ▲ | $509.19M ▲ | $-58.62M ▼ | -15.81% ▼ | $-18.02 ▼ | $-96.21M ▼ |
| Q3-2024 | $362.12M | $469.11M | $-46.51M | -12.84% | $-14.37 | $-79.14M |
What's going well?
The company managed to generate some other income this quarter, which provided a small offset to losses. Share count remains stable, so dilution isn't hurting shareholders.
What's concerning?
Revenue is falling, costs now exceed sales, and losses are getting worse. Interest expense doubled, and the company is losing money on every sale.
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q3-2025 | $37.71M ▼ | $683.56M ▼ | $664.64M ▲ | $-18.69M ▼ |
| Q2-2025 | $38.58M ▼ | $731.59M ▼ | $644.41M ▼ | $44.46M ▼ |
| Q1-2025 | $40.08M ▲ | $783.87M ▲ | $662.79M ▲ | $63.25M ▼ |
| Q4-2024 | $38.82M ▼ | $783.42M ▼ | $633.89M ▲ | $75.94M ▼ |
| Q3-2024 | $62.96M | $833.33M | $569.42M | $120.51M |
What's financially strong about this company?
Debt has been reduced sharply, and payables are much lower than last quarter. There is no goodwill, and cash plus receivables still make up a sizable chunk of assets.
What are the financial risks or weaknesses?
The company has negative equity, very weak liquidity, and most assets are intangible. Cash is low, and current liabilities far exceed current assets, raising serious survival concerns.
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q3-2025 | $-31.59M ▲ | $-15.41M ▲ | $-119K ▼ | $14.67M ▲ | $-865K ▲ | $-15.53M ▲ |
| Q2-2025 | $-43.66M ▲ | $-16.63M ▲ | $50K ▲ | $14.62M ▼ | $-1.97M ▲ | $-16.63M ▲ |
| Q1-2025 | $-44.25M ▲ | $-33.47M ▲ | $0 ▲ | $30.66M ▼ | $-2.81M ▲ | $-33.47M ▲ |
| Q4-2024 | $-58.62M ▼ | $-57.24M ▼ | $-475K ▼ | $33.72M ▲ | $-24M ▼ | $-57.24M ▼ |
| Q3-2024 | $-46.51M | $-22.62M | $15M | $-2.49M | $-10.1M | $-22.62M |
What's strong about this company's cash flow?
Cash burn is shrinking, and the company still has $38.5 million in cash. Working capital moves helped boost cash this quarter.
What are the cash flow concerns?
The business is not generating cash from operations and is dependent on borrowing to survive. The working capital benefit is likely a one-off, and cash will run out in a few quarters without more funding.
Revenue by Products
| Product | Q3-2024 | Q4-2024 | Q1-2025 | Q2-2025 |
|---|---|---|---|---|
Capitated Revenue | $360.00M ▲ | $740.00M ▲ | $370.00M ▼ | $350.00M ▼ |
Health Care Patient Service | $0 ▲ | $10.00M ▲ | $0 ▼ | $0 ▲ |
Q3 2025 Earnings Call Summary
Read Call Summary5-Year Trend Analysis
A comprehensive look at P3 Health Partners Inc.'s financial evolution and strategic trajectory over the past five years.
P3 combines rapid revenue growth with a business model that is aligned with long-term trends in healthcare: a shift toward value-based care, aging demographics, and a desire to manage chronic conditions more effectively. Its physician-led governance, high reported physician retention, and capital-light affiliate network support scalability without massive physical infrastructure. The proprietary technology platform, data-driven care programs, and partnerships with advanced analytics providers give it a modern toolset to manage risk and coordinate care, and it has demonstrated an ability to raise capital to support its expansion to date.
The central risk is financial: persistent net losses, worsening free cash flow, rising leverage, and thinning liquidity all point to a business that has not yet proven its economic sustainability. Negative retained earnings and declining equity reduce its buffer against shocks, while increasing debt raises sensitivity to interest rates and refinancing conditions. Operationally, the company faces significant execution risk in its turnaround plan, must manage complex relationships with payors and regulators in the Medicare Advantage space, and competes against larger and better-capitalized players. Any tightening in capital markets, adverse policy change, or misstep in controlling medical costs could materially strain the business.
The near-term outlook is dominated by the planned shift from rapid expansion to disciplined profitability. Management’s focus on narrowing to its strongest markets, improving medical expense management, and leveraging its technology and partnerships for better operating performance reflects a deliberate attempt to turn a high-growth but loss-making model into a sustainable platform. If the turnaround succeeds, the company could emerge with a more focused footprint, better margins, and a clearer path to self-funded growth. If it falls short, continued cash burn and balance sheet pressure may constrain strategic options. Investors and stakeholders will likely pay close attention to trends in operating margins, cash burn, and membership quality rather than just top-line growth in the coming years.
About P3 Health Partners Inc.
https://p3hp.orgP3 Health Partners Inc. provides primary health care services. The company offers clinical operations and population health management services, as well as provides senior wellness centers. The company is based in Henderson, Nevada.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q3-2025 | $345.25M ▼ | $19.69M ▼ | $-31.59M ▼ | -9.15% ▼ | $-9.67 ▼ | $-27.89M ▼ |
| Q2-2025 | $355.79M ▼ | $389.91M ▲ | $-20.36M ▲ | -5.72% ▼ | $-6.23 ▲ | $-10.46M ▲ |
| Q1-2025 | $373.23M ▲ | $32.31M ▼ | $-20.48M ▲ | -5.49% ▲ | $-6.28 ▲ | $-13.4M ▲ |
| Q4-2024 | $370.69M ▲ | $509.19M ▲ | $-58.62M ▼ | -15.81% ▼ | $-18.02 ▼ | $-96.21M ▼ |
| Q3-2024 | $362.12M | $469.11M | $-46.51M | -12.84% | $-14.37 | $-79.14M |
What's going well?
The company managed to generate some other income this quarter, which provided a small offset to losses. Share count remains stable, so dilution isn't hurting shareholders.
What's concerning?
Revenue is falling, costs now exceed sales, and losses are getting worse. Interest expense doubled, and the company is losing money on every sale.
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q3-2025 | $37.71M ▼ | $683.56M ▼ | $664.64M ▲ | $-18.69M ▼ |
| Q2-2025 | $38.58M ▼ | $731.59M ▼ | $644.41M ▼ | $44.46M ▼ |
| Q1-2025 | $40.08M ▲ | $783.87M ▲ | $662.79M ▲ | $63.25M ▼ |
| Q4-2024 | $38.82M ▼ | $783.42M ▼ | $633.89M ▲ | $75.94M ▼ |
| Q3-2024 | $62.96M | $833.33M | $569.42M | $120.51M |
What's financially strong about this company?
Debt has been reduced sharply, and payables are much lower than last quarter. There is no goodwill, and cash plus receivables still make up a sizable chunk of assets.
What are the financial risks or weaknesses?
The company has negative equity, very weak liquidity, and most assets are intangible. Cash is low, and current liabilities far exceed current assets, raising serious survival concerns.
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q3-2025 | $-31.59M ▲ | $-15.41M ▲ | $-119K ▼ | $14.67M ▲ | $-865K ▲ | $-15.53M ▲ |
| Q2-2025 | $-43.66M ▲ | $-16.63M ▲ | $50K ▲ | $14.62M ▼ | $-1.97M ▲ | $-16.63M ▲ |
| Q1-2025 | $-44.25M ▲ | $-33.47M ▲ | $0 ▲ | $30.66M ▼ | $-2.81M ▲ | $-33.47M ▲ |
| Q4-2024 | $-58.62M ▼ | $-57.24M ▼ | $-475K ▼ | $33.72M ▲ | $-24M ▼ | $-57.24M ▼ |
| Q3-2024 | $-46.51M | $-22.62M | $15M | $-2.49M | $-10.1M | $-22.62M |
What's strong about this company's cash flow?
Cash burn is shrinking, and the company still has $38.5 million in cash. Working capital moves helped boost cash this quarter.
What are the cash flow concerns?
The business is not generating cash from operations and is dependent on borrowing to survive. The working capital benefit is likely a one-off, and cash will run out in a few quarters without more funding.
Revenue by Products
| Product | Q3-2024 | Q4-2024 | Q1-2025 | Q2-2025 |
|---|---|---|---|---|
Capitated Revenue | $360.00M ▲ | $740.00M ▲ | $370.00M ▼ | $350.00M ▼ |
Health Care Patient Service | $0 ▲ | $10.00M ▲ | $0 ▼ | $0 ▲ |
Q3 2025 Earnings Call Summary
Read Call Summary5-Year Trend Analysis
A comprehensive look at P3 Health Partners Inc.'s financial evolution and strategic trajectory over the past five years.
P3 combines rapid revenue growth with a business model that is aligned with long-term trends in healthcare: a shift toward value-based care, aging demographics, and a desire to manage chronic conditions more effectively. Its physician-led governance, high reported physician retention, and capital-light affiliate network support scalability without massive physical infrastructure. The proprietary technology platform, data-driven care programs, and partnerships with advanced analytics providers give it a modern toolset to manage risk and coordinate care, and it has demonstrated an ability to raise capital to support its expansion to date.
The central risk is financial: persistent net losses, worsening free cash flow, rising leverage, and thinning liquidity all point to a business that has not yet proven its economic sustainability. Negative retained earnings and declining equity reduce its buffer against shocks, while increasing debt raises sensitivity to interest rates and refinancing conditions. Operationally, the company faces significant execution risk in its turnaround plan, must manage complex relationships with payors and regulators in the Medicare Advantage space, and competes against larger and better-capitalized players. Any tightening in capital markets, adverse policy change, or misstep in controlling medical costs could materially strain the business.
The near-term outlook is dominated by the planned shift from rapid expansion to disciplined profitability. Management’s focus on narrowing to its strongest markets, improving medical expense management, and leveraging its technology and partnerships for better operating performance reflects a deliberate attempt to turn a high-growth but loss-making model into a sustainable platform. If the turnaround succeeds, the company could emerge with a more focused footprint, better margins, and a clearer path to self-funded growth. If it falls short, continued cash burn and balance sheet pressure may constrain strategic options. Investors and stakeholders will likely pay close attention to trends in operating margins, cash burn, and membership quality rather than just top-line growth in the coming years.

CEO
Aric Coffman
Compensation Summary
(Year 2024)
Ratings Snapshot
Rating : C
Price Target
Institutional Ownership
LMR PARTNERS LLP
Shares:2.55M
Value:$16.56K
WALLEYE CAPITAL LLC
Shares:1.99M
Value:$12.96K
TORONTO DOMINION BANK
Shares:522.92K
Value:$3.4K
Summary
Showing Top 3 of 27

